Literature DB >> 10022447

Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro.

H F Chen1, E B Jeung, M Stephenson, P C Leung.   

Abstract

The hypothalamic decapeptide, GnRH, plays a critical role in human reproduction. In addition to the well known effects of GnRH on pituitary cells, there is evidence supporting the presence of GnRH-binding sites in tissues other than pituitary cells, including lymphocytes. In addition, a GnRH-like substance has been found to be secreted from lymphoid cells. However, the precise nature of GnRH secretion and binding in immune cells has not been fully established. In this study, we used the RT-PCR method to examine the expression and regulation of GnRH, GnRH receptor (GnRHR), and interleukin-2 receptor gamma-chain messenger ribonucleic acids (mRNAs) in human peripheral blood mononuclear cells. It was found that human mononuclear cells expressed GnRH and GnRHR mRNAs. Nucleotide sequences of these mRNAs are identical to their hypothalamic and pituitary counterparts, respectively. In addition, GnRH and GnRHR mRNA expressions in peripheral blood mononuclear cells are regulated by GnRH and its synthetic analogs in vitro. Treatment with various concentrations of GnRH (10(-5)-10(-11) mol/L) increased GnRHR mRNA expression in a dose-dependent manner (maximal level is 158% of the untreated control value at 10(-8) mol/L GnRH; P < 0.05), but reduced GnRH mRNA levels to 69% of the untreated control value at 10(-9) mol/L GnRH (P < 0.05). Cotreatment of GnRH with a GnRH antagonist blocked these regulatory effects, indicating the receptor-mediated nature of the GnRH action. Both GnRH and GnRH agonist stimulated interleukin-2 receptor gamma-chain mRNA in a dose-dependent manner, indicating that GnRH may be involved in lymphocyte activation. In summary, these observations suggest that mRNAs encoding the pituitary form of GnRHR and the hypothalamic form of GnRH are also expressed in human peripheral blood mononuclear cells. The endogenous production of GnRH by lymphocytes may act as an autocrine or paracrine factor to regulate immune functions. Because of the presence of GnRHR on lymphocytes, exogenous GnRH analog therapy may have an impact on the immune system through these receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022447     DOI: 10.1210/jcem.84.2.5440

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  33 in total

1.  Mast cells in the rat brain synthesize gonadotropin-releasing hormone.

Authors:  Mona H Khalil; Ann-Judith Silverman; Rae Silver
Journal:  J Neurobiol       Date:  2003-08

2.  Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains.

Authors:  O Moran; L J V Galietta; O Zegarra-Moran
Journal:  Cell Mol Life Sci       Date:  2005-02       Impact factor: 9.261

3.  Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.

Authors:  Matthew R Smith; Laurence Klotz; Egbert van der Meulen; Enrico Colli; László B Tankó
Journal:  J Urol       Date:  2011-09-25       Impact factor: 7.450

4.  Stability, permeability and growth-inhibitory properties of gonadotropin-releasing hormone liposaccharides.

Authors:  Daryn Goodwin; Pegah Varamini; Pavla Simerska; Istvan Toth
Journal:  Pharm Res       Date:  2014-11-19       Impact factor: 4.200

Review 5.  Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.

Authors:  Timothy N Clinton; Solomon L Woldu; Ganesh V Raj
Journal:  Expert Opin Pharmacother       Date:  2017-05-19       Impact factor: 3.889

6.  GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males.

Authors:  F Tanriverdi; D Gonzalez-Martinez; Y Hu; F Kelestimur; P M G Bouloux
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 7.  [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].

Authors:  C Tschöpe; B Kherad; F Spillmann; C A Schneider; B Pieske; F Krackhardt
Journal:  Herz       Date:  2016-04-15       Impact factor: 1.443

8.  Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system.

Authors:  Andrew V Kossenkov; Anil Vachani; Celia Chang; Calen Nichols; Shere Billouin; Wenhwai Horng; William N Rom; Steven M Albelda; Michael K Showe; Louise C Showe
Journal:  Clin Cancer Res       Date:  2011-08-01       Impact factor: 12.531

Review 9.  Effects of gonadotrophin-releasing hormone outside the hypothalamic-pituitary-reproductive axis.

Authors:  D C Skinner; A J Albertson; A Navratil; A Smith; M Mignot; H Talbott; N Scanlan-Blake
Journal:  J Neuroendocrinol       Date:  2009-03       Impact factor: 3.627

Review 10.  Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?

Authors:  Piotr Zareba; Wilhelmina Duivenvoorden; Darryl P Leong; Jehonathan H Pinthus
Journal:  Ther Adv Urol       Date:  2015-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.